JP2018516911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516911A5 JP2018516911A5 JP2017561621A JP2017561621A JP2018516911A5 JP 2018516911 A5 JP2018516911 A5 JP 2018516911A5 JP 2017561621 A JP2017561621 A JP 2017561621A JP 2017561621 A JP2017561621 A JP 2017561621A JP 2018516911 A5 JP2018516911 A5 JP 2018516911A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antagonist
- cancer
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021041014A JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168449P | 2015-05-29 | 2015-05-29 | |
| US62/168,449 | 2015-05-29 | ||
| US201562169309P | 2015-06-01 | 2015-06-01 | |
| US62/169,309 | 2015-06-01 | ||
| PCT/US2016/034275 WO2016196173A1 (en) | 2015-05-29 | 2016-05-26 | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041014A Division JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516911A JP2018516911A (ja) | 2018-06-28 |
| JP2018516911A5 true JP2018516911A5 (enExample) | 2019-06-27 |
| JP6893608B2 JP6893608B2 (ja) | 2021-06-23 |
Family
ID=57441888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561621A Active JP6893608B2 (ja) | 2015-05-29 | 2016-05-26 | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| JP2021041014A Active JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041014A Active JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10751412B2 (enExample) |
| EP (2) | EP3892284B1 (enExample) |
| JP (2) | JP6893608B2 (enExample) |
| KR (1) | KR20180014009A (enExample) |
| CN (1) | CN108025018B (enExample) |
| AU (1) | AU2016271018A1 (enExample) |
| BR (1) | BR112017025562A2 (enExample) |
| CA (1) | CA2986126A1 (enExample) |
| ES (1) | ES2985394T3 (enExample) |
| MA (1) | MA44699A (enExample) |
| MX (1) | MX2017015308A (enExample) |
| RU (1) | RU2017145558A (enExample) |
| WO (1) | WO2016196173A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CA2906502A1 (en) | 2013-03-13 | 2014-10-02 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
| US12558316B2 (en) | 2013-03-13 | 2026-02-24 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2016057898A1 (en) * | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| SI3240801T1 (sl) * | 2014-12-31 | 2021-04-30 | Checkmate Pharmaceuticals, Inc. | Kombinirana imunoterapija tumorja |
| EP3892284B1 (en) | 2015-05-29 | 2024-05-22 | Merck Sharp & Dohme LLC | Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| IL292658A (en) | 2016-09-15 | 2022-07-01 | Idera Pharmaceuticals Inc | Immune modulation with tlr9 agonists for cancer treatment |
| MX2019012741A (es) | 2017-04-28 | 2020-01-21 | Merck Sharp & Dohme | Biomarcadores para agentes terapeuticos contra el cancer. |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| EP3694520A1 (en) | 2017-10-13 | 2020-08-19 | Merck Sharp & Dohme Corp. | Compositions and methods for treating diffuse large b cell lymphoma |
| WO2019084418A1 (en) | 2017-10-27 | 2019-05-02 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER |
| EP3752194A4 (en) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| SG11202009647VA (en) | 2018-04-09 | 2020-10-29 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| WO2019200238A1 (en) * | 2018-04-14 | 2019-10-17 | Dynavax Technologies Corporation | Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer |
| WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| US20220010008A1 (en) * | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| CN111321159B (zh) * | 2018-12-14 | 2023-12-12 | 中天(上海)生物科技有限公司 | 用于免疫调节的嵌合核酸分子及其应用 |
| TWI833056B (zh) | 2019-12-31 | 2024-02-21 | 財團法人工業技術研究院 | 核酸藥物複合體以及其用途 |
| MX2022005633A (es) * | 2020-01-10 | 2022-06-14 | Sbi Biotech Co Ltd | Novedosos agonistas del receptor tipo toll 9 (tlr9). |
| CN116724118A (zh) * | 2020-07-24 | 2023-09-08 | 利兰斯坦福初级大学董事会 | Covid-19的三组分疫苗 |
| CN116685330A (zh) * | 2020-09-22 | 2023-09-01 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| EP4216930A4 (en) * | 2020-09-22 | 2024-08-07 | Trisalus Life Sciences, Inc. | CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS |
| US20230364125A1 (en) * | 2020-09-22 | 2023-11-16 | Trisalus Life Sciences, Inc. | Cancer therapy using toll-like receptor agonists |
| WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
| EP4313315A4 (en) * | 2021-04-01 | 2025-02-19 | TriSalus Life Sciences, Inc. | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS |
| CN117561066A (zh) * | 2021-04-01 | 2024-02-13 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023081486A1 (en) | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド／免疫調節分子複合体 |
| WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| DK1009413T3 (da) | 1997-09-05 | 2007-06-11 | Univ California | Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| AU4343700A (en) | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
| NZ526322A (en) | 2000-12-27 | 2005-06-24 | Dynavax Tech Corp | Immunomodulatory polynucleotides and methods of using the same |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| ATE544772T1 (de) * | 2002-12-23 | 2012-02-15 | Dynavax Tech Corp | Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3243527B1 (en) * | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| MX341076B (es) | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP6312659B2 (ja) | 2012-05-31 | 2018-04-18 | ジェネンテック， インコーポレイテッド | Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| RU2016107426A (ru) * | 2013-08-02 | 2017-09-07 | Адуро Байотек Холдингс, Юроуп Б.В. | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета |
| KR20160060765A (ko) * | 2013-10-11 | 2016-05-30 | 제넨테크, 인크. | 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도 |
| WO2015167616A1 (en) | 2014-05-02 | 2015-11-05 | Nitor Therapeutics | Guanosine as an immunepotentiator mediated through toll receptors |
| WO2016057898A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| SI3240801T1 (sl) | 2014-12-31 | 2021-04-30 | Checkmate Pharmaceuticals, Inc. | Kombinirana imunoterapija tumorja |
| EP3892284B1 (en) | 2015-05-29 | 2024-05-22 | Merck Sharp & Dohme LLC | Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer |
| WO2016196178A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer |
-
2016
- 2016-05-26 EP EP21159163.1A patent/EP3892284B1/en active Active
- 2016-05-26 ES ES21159163T patent/ES2985394T3/es active Active
- 2016-05-26 MX MX2017015308A patent/MX2017015308A/es unknown
- 2016-05-26 US US15/577,369 patent/US10751412B2/en active Active
- 2016-05-26 CA CA2986126A patent/CA2986126A1/en not_active Abandoned
- 2016-05-26 BR BR112017025562A patent/BR112017025562A2/pt not_active Application Discontinuation
- 2016-05-26 JP JP2017561621A patent/JP6893608B2/ja active Active
- 2016-05-26 AU AU2016271018A patent/AU2016271018A1/en not_active Abandoned
- 2016-05-26 RU RU2017145558A patent/RU2017145558A/ru not_active Application Discontinuation
- 2016-05-26 EP EP16804054.1A patent/EP3302501B1/en active Active
- 2016-05-26 KR KR1020177037185A patent/KR20180014009A/ko not_active Withdrawn
- 2016-05-26 MA MA044699A patent/MA44699A/fr unknown
- 2016-05-26 WO PCT/US2016/034275 patent/WO2016196173A1/en not_active Ceased
- 2016-05-26 CN CN201680043989.1A patent/CN108025018B/zh active Active
-
2020
- 2020-08-21 US US17/000,149 patent/US11918648B2/en active Active
-
2021
- 2021-03-15 JP JP2021041014A patent/JP7236483B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021102627A5 (enExample) | ||
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2017524715A5 (enExample) | ||
| JP2017537070A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| Lote et al. | PD-1 and PD-L1 blockade in gastrointestinal malignancies | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| JP2015532292A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| JP2017506264A5 (enExample) | ||
| WO2015112805A8 (en) | Human antibodies to pd-l1 | |
| HRP20241325T1 (hr) | Kombinirana terapija za melanom | |
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| JP2018008963A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| NZ600281A (en) | Compositions and methods for the treatment of infections and tumors | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| JP2020502271A5 (enExample) | ||
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2018518454A5 (enExample) | ||
| RU2016104880A (ru) | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit | |
| JP2018508512A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2015517300A5 (enExample) |